General
Preferred name
CILAZAPRIL
Synonyms
Ro 31-2848 ()
Cilazapril (monohydrate) ()
Ro 31-2848 monohydrate ()
Cilazapril Monohydrate ()
Cilazaprilum ()
Justor ()
Anhydrous cilazapril ()
Inhibace ()
Initiss ()
Cilazapril monohydrate ()
RO-312848006 ()
Vascace ()
Cilazapril anhydrous ()
Cilazapril hydrate ()
RO 31-2848/006 ()
P&D ID
PD009546
CAS
92077-78-6
88768-40-5
Tags
prodrug
natural product
drug
available
Drug Status
approved
withdrawn
Drug indication
Congestive heart failure
Antihypertensive
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Cilazapril is a prodrug. It is metabolically converted to the drug cilazaprilat. Cilazapril does not appear to have marketing approval for human use in the US or EU, although national approval agencies may have granted marketing authorisation.
(GtoPdb)
ABSORPTION
Maximum plasma concentrations of cilazaprilat are reached within two hours after; administration of cilazapril.
DESCRIPTION
Cilazapril is a angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
15
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NPC Screening Collection
ReFrame library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
43
Molecular Weight
417.23
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
1
cLogP
1.6
TPSA
99.18
Fraction CSP3
0.59
Chiral centers
3.0
Largest ring
7.0
QED
0.62
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Angiotensin-converting Enzyme (ACE)
ACE
Pathway
Metabolic Enzyme/Protease
Indication
hypertension, congestive heart failure
MOA
angiotensin converting enzyme inhibitor
Therapeutic Class
Antihypertensive Agents
Source data
